Production & Manufacturing
Production & Manufacturing
Novartis announces agreement to develop influenza vaccines using revolutionary synthetic genomics technology
Novartis announced today an agreement with Synthetic Genomics Vaccines Inc. (SGVI) to apply "synthetic genomics" technologies to accelerate the production of the influenza seed strains required for vaccine manufacturing. The seed strain is the starter culture of a virus,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.